Docetaxel Trihydrate Powder, with the CAS number 114977-28-5, represents a significant advancement in the field of oncology. This pharmaceutical-grade raw material is a potent semi-synthetic taxane derivative, renowned for its efficacy as a cytotoxic agent in the treatment of various advanced cancers. Its primary mechanism of action involves the stabilization of microtubules, which are essential components for cell division. By disrupting the normal functioning of the mitotic spindle, Docetaxel Trihydrate Powder effectively halts the proliferation of cancer cells and induces apoptosis, or programmed cell death.

The clinical significance of this compound is evident in its widespread use across multiple cancer types. It plays a crucial role in the treatment of metastatic breast cancer, offering improved outcomes when administered as part of combination chemotherapy regimens. For patients with non-small cell lung cancer (NSCLC), Docetaxel Trihydrate Powder serves as an important second-line treatment, providing a significant survival advantage. Furthermore, its application in hormone-refractory prostate cancer has transformed patient care, offering a vital therapeutic option. The versatility of this pharmaceutical intermediate extends to gastric adenocarcinoma and head and neck cancers, underscoring its broad therapeutic reach.

NINGBO INNO PHARMCHEM CO.,LTD. understands the critical importance of this raw material and is dedicated to ensuring its availability and quality. As a supplier of essential pharmaceutical intermediates, the company plays a vital role in the supply chain for advanced cancer treatments. The consistent delivery of high-purity Docetaxel Trihydrate Powder empowers researchers and pharmaceutical manufacturers to develop and produce effective chemotherapy drugs. The ongoing research into optimizing its delivery and minimizing side effects further highlights the enduring importance of this potent anticancer agent in modern medicine.